India’s top policy think-tank Niti Aayog unveiled a Rs 50,000-crore BioEconomy Growth Fund and a six-mission roadmap aimed at lifting the country’s bioeconomy to $691 billion by 2035. The plan promises more than 30 million high-value jobs and a handful of globally competitive biotech firms, a shift that could reshape manufacturing, agriculture and health across the nation.

Why the roadmap matters

The bioeconomy—businesses that turn biological resources into products—now accounts for 4.8 % of India’s GDP, worth $195.3 billion after a 16-fold jump in a decade. Most of that value still sits in research labs, not factories. Niti Aayog’s roadmap swaps scattered programs for six coordinated national missions and a dedicated fund to push discoveries into large-scale production, a move meant to curb imports and boost exports of biomanufactured goods.

The six missions

  • GeneIndia – develops affordable gene therapies and precision diagnostics.
  • AgriBio 2.0 – creates climate-resilient crops and bio-inputs such as bio-fertilisers to protect yields as weather patterns shift.
  • BioX Foundry – links synthetic-biology research with market launch, turning engineered microbes into commercial chemicals and materials.
  • One Health Grid – uses AI tools to monitor diseases across humans, animals and the environment, echoing the “one health” concept.
  • Marine Biotechnology – expands seaweed farming and extracts marine compounds, tapping a largely untapped resource base.
  • BioPharmaNext – builds centres for biologics, vaccines and drug discovery, aiming to cut dependence on imported medicines.

Funding and institutional set-up

The Rs 50,000-crore fund, spread over 2026-2035, will finance the shift from lab research to full-scale manufacturing. Niti Aayog will create an Empowered Committee on National BioMissions to steer the work, a National BioData Council to manage data sharing, and a BioEconomy Investment and Policy Forum to lure private capital. A fast-track system for IP approvals and PLI-style incentives—financial rewards tied to production volumes—will accelerate commercialization.

Potential impact on jobs and industry

Niti Aayog estimates the roadmap could generate over 30 million high-skill jobs, from biotech engineers to data scientists in disease-surveillance networks. It also targets the creation of 15 globally competitive biotechnology companies, a benchmark meant to lift India into the top tier of the sector’s global value chain.

Challenges and criticisms

What to watch

  • How the Rs 50,000-crore fund is allocated across missions and when money will be disbursed.
  • How quickly the Empowered Committee and BioData Council become operational.
  • Early rollout of PLI-style incentives and the response from domestic and foreign investors.
  • Regulatory outcomes for gene-therapy and AI-based health surveillance, which will signal the balance between speed and safety.

Takeaway: Niti Aayog’s bioeconomy roadmap delivers a massive financial push and a coordinated mission structure that could turn India into a leading biotech manufacturing hub, but success hinges on implementation, transparent regulation and support for firms of all sizes.